PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, monocentre, phase 2 trial: minotaURO study
This research study, called the minotaURO study, is testing a new treatment approach for people with bladder cancer that has spread to other parts of the body. It combines two different types of medication: pembrolizumab (a type of immunotherapy that helps your own immune system fight cancer) and a low-dose, regular chemotherapy drug called cyclophosphamide (Endoxan®). The main aim is to see if this combination can stop the cancer from growing or spreading for at least six months. Researchers are also looking at how long people respond to the treatment, if it shrinks the tumors, how safe it is, and what side effects might occur. We're also trying to find signs in blood and tissue samples that help us understand why some people respond better than others.
At a glance
What is this study about?
This study is looking into a new way to treat bladder cancer that has spread to other parts of the body. When cancer spreads, it's called 'metastatic.' Doctors are trying out a combination of two medicines: pembrolizumab and cyclophosphamide. Pembrolizumab is a modern type of treatment called immunotherapy. It works by boosting your own body's immune system to recognise and fight cancer cells. Cyclophosphamide is a chemotherapy drug, but in this study, it's given in a low, regular dose. The main goal is to see if this combination can help stop the cancer from getting worse for a period of at least six months. This is important because it means potentially more time where the cancer is stable, which can improve quality of life.
The study also aims to understand how well the treatment works in other ways. For example, they'll be looking at how long people remain stable or respond to the treatment, if it helps shrink the cancer, and how long people live overall. Importantly, they are also studying the safety of this new combination and identifying any side effects.
Finally, this research includes an exploratory part where scientists will look at blood and tissue samples. They want to find 'biomarkers' – these are like clues in your body that can help us understand why some people respond well to this treatment and others don't. This could help doctors in the future to choose the best treatments for individual patients.
Key takeaways
- This study is testing a new combined treatment for advanced bladder cancer.
- It uses immunotherapy (pembrolizumab) and a low-dose chemotherapy (cyclophosphamide).
- The main goal is to see if the treatment can stop cancer growth for at least six months.
- Researchers are also looking at treatment safety, effectiveness, and biological markers.
- It's for adults aged 18 and over, of any sex.
Who may be eligible?
To be part of this study, you need to be an adult, 18 years old or older. The study is open to both men and women.
More detailed specific health checks will be done by the study team to make sure it's safe for you to take part and that the results of the study will be clear. For example, doctors will check your overall health and make sure your cancer is of a specific type (urothelial cancer) and has spread.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have urothelial cancer that has spread?
- Are you able to attend regular hospital visits for tests and treatments?
- Are you willing for doctors to collect blood and tissue samples for research?
What does participation involve?
If you decide to join this study, you will receive regular doses of the study medicines: pembrolizumab and cyclophosphamide. Pembrolizumab is usually given as an infusion into a vein, and cyclophosphamide is taken as tablets. You will have regular hospital visits for check-ups, blood tests, and scans to see how your body is reacting to the treatment and how the cancer is responding. These visits will be more frequent at the beginning and then might become less often if things are going well. The total duration of your participation will depend on how you respond to the treatment and the study plan, but you will be monitored closely throughout.
Potential risks and benefits
Locations (1)
- —UnverifiedItaly
Common questions
What is urothelial cancer?
Urothelial cancer is a type of cancer that starts in the lining of the urinary system, most commonly the bladder.
What does 'metastatic' mean?
Metastatic means the cancer has spread from where it started to other parts of the body.
What is immunotherapy?
Immunotherapy is a treatment that helps your body's own immune system fight cancer.
What are 'biomarkers'?
Biomarkers are substances in your body that can give doctors clues about your health or how a treatment might work for you.
Will I have to pay to be in the study?
No, all study-related treatments and tests are provided at no cost to you.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.